
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Dr Annunziata (Nancy) Dattola is Researcher at the Department of Dermatology, University of La Sapienza in Rome, Italy.
Her main field of interest is the diagnosis and treatment of inflammatory skin diseases. In 2013, Dr Dattola completed a 2-year fellowship at the Laboratory for Investigative Dermatology at the Rockefeller University, New York, NY. During her fellowship, she focused on psoriasis, metabolic syndrome and imaging such as positron emission tomography (PET)/computerised tomography (CT), sono-elastography, and CT angiography, in the diagnosis of patients with psoriasis. In January 2021, she completed her PhD in Biochemistry and Molecular Biology with a thesis entitled: “Results of two different biological treatments in patients with PsO and PsA, and detection of early arthritis”.
Dr Dattola’s current research includes projects on biological agents for the treatment of psoriasis, laser and cosmetology. She is also involved in numerous phase III clinical trials and is author of many papers on these topics. She completed 3 years of research at the University of Rome Tor Vergata from 2018 to 2021.
Dr Dattola is a member of the “Italian task force” for women with psoriasis, member of the Italian Society of Dermatology and Venereology (SIDeMaST), member of the European Academy of Dermatology and Venereology (EADV) and member of the local organising committee for the World Congress of Dermatology 2019 Milan, Italy.
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.